Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6700-0.0450 (-1.21%)
At close: 4:00PM EDT
3.5500 -0.12 (-3.27%)
After hours: 07:16PM EDT
Advertisement
Sign in to post a message.
  • V
    VenkatS
    Accumulation has to happen this week as the Q closes! Mutual funds and institutions should be buying.

    I am expecting them to release new updates before Sept 30 (before the Fireside chat! )
    Bullish
  • s
    scott
    A good day, news soon?
  • s
    scott
    I will buy more under 4.
  • V
    VenkatS
    I am expecting this is the month, all the institutions will start loading this stock for better days to come!

    I am also expecting new partnership to reveal this month!

    Expecting to hear nothing but stellar news about ongoing trails at the Fire chat conversations...

    Above all, I want to see retail activity in buying and selling shares... and sharing their opinions in the chat room.

    I am long and bullish!
    Bullish
  • V
    VenkatS
    Really interested in knowing the history of this company, if anyone has. Looks like some kind of Merging and reverse splitting happened years ago.....Need to know

    Based on the cash position they are in and the pipeline in works, I put this share around $ 10-$12 easily. THere is good potential for it to grow.
    Bullish
  • V
    VenkatS
    Here are the catalysts for this Stock;

    Analysts Target - $22

    Target - $22
    AVB-500 – FDA Fast Track Granted & Five Clinical Trails in progress
    Interim analysis for Phase 3 PROC trial (Q1 2022) – Very important milestone for this company!
    AVB-500 Investigator Sponsored Trials in Progress. One of the two or both could progress to the next level.
    Phase 1b Trial of AVB-500 in Combination with Cabozantinib - First patient dosed in March 2021; Completion of enrollment expected in Q3 2021 and Initiation of Phase 2 trial expected in Q4 2021

    Phase 1b Trial of AVB-500 in Combination with Gemcitabine + nab-Paclitaxel First patient dosed in Phase 1b portion of trial in August 2021; Completion of enrollment expected in first half of 2022

    28% ownership by insiders – Says a lot about the company
    Bullish
  • K
    K
    Holding the bag that keeps bottom hole getting bigger by the day.
  • E
    ERIC
    Yesterday—the Whitehouse announced $6.5 billion dollars worth of funding for cancer research with ovarian cancer being the focus. I wonder if the management at Aravive is smart enough to apply for a grant? Let’s blow up investor relations email and tell them about it!!!!!
  • J
    Jazzman
    This stock use to be over $100 five years ago. This thing just keeps going lower. Seems like management is inept and can't get out of their own way. Pure speculation at this time.
  • V
    VenkatS
    Earnings are out. They beat by 3 cents.

    As per the report, they are progressing well with their pipeline.

    They have good Cash position. Actually their cash position improved with Partner payments etc.

    They have enough cash to buyout themselves... I don't know why this stock is this low.... I see no volume. It needs some attention from retail investors.

    It seems to be a very rewarding bet for me!
    Bullish
  • s
    shayla
    So why does YAHOO not let me post about this morning's news?
  • C
    Chari
    Lets keep the news flowing..

    Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
    31 minutes ago
    GlobeNewswire
    Related Investments: Aravive Inc
    --Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, and 3 D Medicines Inc., a China- based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced a collaboration and exclusive license agreement for the development and commercialization of AVB-500 across all oncology...
  • J
    Julian
    “We are enthusiastic about the clinical data with AVB-500 in combination with anticancer therapies that continue to show consistent PK/PD data and a favorable safety profile. These combinations may have the potential to be used in a range of different cancers.”

    It’s important that at any stage a drug can fail, but “consistent PK/PD” is one of the fastest and difficult to predict ways. I think this will creep up like all biotech as the probability of getting to the market vets higher and higher
  • T
    Trevor
    Just remember, a board member purchased 2.875 million shares of common stock at $7.29 pps. Anything under that price is a great entry point IMO. I’m holding about 6,000 shares around current price since last year. Could have sold in March and netted over $24k but this baby is going to get a lot closer to the current price target of $26.
  • T
    Tom
    Finally, some sort of move.
  • D
    DoyourownDD
    Arav currently approx.. $98 Mill Market Cap and $28 Mill Enterprise Value AND lead drug advancing to phase 3 with “Aravive’s collaboration and license agreement with 3D Medicines Inc. is for the development and commercialization of AVB-500 in oncology indications in Greater China. Under the terms of the agreement, Aravive is eligible to receive up to an aggregate of $207 million in development and commercial milestone payments and royalties.”
    wow appears SP may be way undervalued if approved? 207/28=7.25 x 4.5(current stock price)=$32.62/SP based on enterprise value and just greater china potential revenue on lead drug candidate potential??? do your own due diligence. NOT financial advice.
    Bullish
  • d
    dakdan
    yes it does have potential but remember this is only a phase 1 Study still years out before FDA approval
  • s
    scott
    last chance under 5.
  • B
    Bobbafet
    50%? Try 300%... check out their investor presentation cancer is growing at an enormous rate. They have a product that has multiple revenue streams. Even a 500 million market cap in my opinion is low compared to what they have to offer. Their partner with 3D will bring in up to 200 million with royalties just in China. Wait till they expand their product. $$$
    Bullish
  • m
    m
    Looks like fireside chat burning 🔥 shareholders again. At next proxy vote to eliminate all the waste.
Advertisement
Advertisement